TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of SIS Mesh for Anterior Repair: A Pilot Study
Brief Summary: Prolapse occurs when pelvic organs drop down and cause a bulging of the tissues. An "anterior wall prolapse" occurs when the front of the vagina loses its support, and the bladder drops down and rotates into the vaginal opening. The bladder can cause a bulge out of the vagina.

One of the treatment options available is to repair the anterior wall surgically. The goals of surgery are to return the anatomy to its usual position, ensuring that all the pelvic floor organs (bladder, vagina and rectum) can function properly. The ideal surgical repair would also be long lasting.

Two surgical options are routinely performed in Calgary for repair of an anterior compartment prolapse. One option involves fixing the organs back in place using sutures. The other option uses sutures plus a mesh made of small intestine submucosa (SIS) that is already licensed for use in Canada. The SIS mesh is slowly absorbed after it is placed in the pelvic area. The investigators do not know which of these two options is the best surgical procedure. Both may have different advantages that would result in better results. This study is designed to try and find out if one of these procedures is better, and if a larger study may be needed.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Avaulta (surgical procedure using a mesh implant) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional surgery (anterior repair) | Intervention Type: PROCEDURE; Name: Avaulta (surgical procedure using a mesh implant); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional surgery (anterior repair); Assigned to Arm(s): 2
B: Arm Label: Prolift mesh; Type: ACTIVE_COMPARATOR; Interventions: Device: synthetic monofilament polypropylene mesh | Arm Label: Prolapse repair without mesh; Type: ACTIVE_COMPARATOR; Interventions: Device: synthetic monofilament polypropylene mesh | Intervention Type: DEVICE; Name: synthetic monofilament polypropylene mesh; Assigned to Arm(s): Prolapse repair without mesh, Prolift mesh
C: Arm Label: SIS Mesh (Cook Medical); Type: EXPERIMENTAL; Interventions: Device: SIS mesh (Cook Medical), Procedure: Anterior prolapse repair | Arm Label: No-mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterior prolapse repair | Intervention Type: DEVICE; Name: SIS mesh (Cook Medical); Assigned to Arm(s): SIS Mesh (Cook Medical) | Intervention Type: PROCEDURE; Name: Anterior prolapse repair; Assigned to Arm(s): No-mesh, SIS Mesh (Cook Medical)
D: Arm Label: Intervention: Collagen matrix; Type: EXPERIMENTAL; Interventions: Procedure: Collagen Matrix | Arm Label: Native tissue repair; Type: OTHER; Interventions: Procedure: Collagen Matrix | Intervention Type: PROCEDURE; Name: Collagen Matrix; Assigned to Arm(s): Intervention: Collagen matrix, Native tissue repair

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Brief Summary: Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects premature newborns. The condition involves abnormal development of lung tissue and is characterized by inflammation and scarring in the lungs. Treatment with inhaled nitric oxide (iNO) may reduce the incidence of BPD and another commonly associated condition called pulmonary hypertension, which is high blood pressure in the vessels carrying blood to the lungs.. This study will determine if early treatment with low-dose iNO reduces the incidence of BPD, pulmonary hypertension, and death in premature newborns.


Options:
A: Intervention Type: PROCEDURE; Name: mechanical ventilation; Assigned to Arm(s): N/A
B: Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: iNO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: iNO; Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Nitric Oxide (iNO) | Arm Label: Nitrogen (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nitrogen (placebo) | Intervention Type: DRUG; Name: Inhaled Nitric Oxide (iNO); Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: DRUG; Name: Nitrogen (placebo); Assigned to Arm(s): Nitrogen (placebo)
D: Arm Label: Inhaled Nitric Oxide (INO); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitric oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitric oxide; Assigned to Arm(s): Inhaled Nitric Oxide (INO) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis
Brief Summary: The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazax | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
D: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis
Brief Summary: The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
B: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: MK-8237 6 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 12 DU | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 DU | Intervention Type: BIOLOGICAL; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
Brief Summary: This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
B: Arm Label: Cervarix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Procedure: Liquid-based cytology (LBC) sampling, Procedure: Blood sampling | Arm Label: Aimmugen Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Liquid-based cytology (LBC) sampling | Intervention Type: PROCEDURE; Name: Liquid-based cytology (LBC) sampling; Assigned to Arm(s): Aimmugen Group, Cervarix Group | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: Gardasil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 1 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 2 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 3 | Intervention Type: BIOLOGICAL; Name: Comparator: Gardasil; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 1; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 2; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 3; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Parallel Group Comparison on the Influence of a Low Carbohydrate and a Low Fat Hypocaloric 6 Months Diet on Body Weight Reduction, Metabolic and Cardiovascular Variables in Obese Healthy Women and Men.
Brief Summary: The investigators will test the hypothesis that a LOW CARB hypocaloric diet will reduce body weight over six months more than a LOW FAT hypocaloric diet. In addition to body weight, the investigators will measure cardiovascular and metabolic variables and will take blood samples in order to determine whether certain metabolites may predict the diet success.


Options:
A: Arm Label: low fat hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Arm Label: Low carbohydrate hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): Low carbohydrate hypocaloric diet, low fat hypocaloric diet
B: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
C: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet
D: Arm Label: Full fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Full fat dairy | Arm Label: Low fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Low fat dairy | Arm Label: Control group; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Full fat dairy; Assigned to Arm(s): Full fat dairy group | Intervention Type: OTHER; Name: Low fat dairy; Assigned to Arm(s): Low fat dairy group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Parallel Group Comparison on the Influence of a Low Carbohydrate and a Low Fat Hypocaloric 6 Months Diet on Body Weight Reduction, Metabolic and Cardiovascular Variables in Obese Healthy Women and Men.
Brief Summary: The investigators will test the hypothesis that a LOW CARB hypocaloric diet will reduce body weight over six months more than a LOW FAT hypocaloric diet. In addition to body weight, the investigators will measure cardiovascular and metabolic variables and will take blood samples in order to determine whether certain metabolites may predict the diet success.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
C: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo
D: Arm Label: low fat hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Arm Label: Low carbohydrate hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): Low carbohydrate hypocaloric diet, low fat hypocaloric diet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Parallel Group Comparison on the Influence of a Low Carbohydrate and a Low Fat Hypocaloric 6 Months Diet on Body Weight Reduction, Metabolic and Cardiovascular Variables in Obese Healthy Women and Men.
Brief Summary: The investigators will test the hypothesis that a LOW CARB hypocaloric diet will reduce body weight over six months more than a LOW FAT hypocaloric diet. In addition to body weight, the investigators will measure cardiovascular and metabolic variables and will take blood samples in order to determine whether certain metabolites may predict the diet success.


Options:
A: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
B: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
C: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
D: Arm Label: low fat hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Arm Label: Low carbohydrate hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): Low carbohydrate hypocaloric diet, low fat hypocaloric diet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial)
Brief Summary: RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. It is not yet known which treatment regimen is more effective in treating patients with liver cancer.

PURPOSE: This randomized phase II trial is studying radioembolization to see how well it works compared with chemoembolization in treating patients with liver cancer that cannot be treated with Radiofrequency Ablation or removed by surgery.


Options:
A: Arm Label: Sorafenib, Multikinase Inhibitor, Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib tosylate | Arm Label: SIR-Spheres, Microspheres, Device; Type: ACTIVE_COMPARATOR; Interventions: Device: SIR-Spheres | Intervention Type: DEVICE; Name: SIR-Spheres; Assigned to Arm(s): SIR-Spheres, Microspheres, Device | Intervention Type: DRUG; Name: Sorafenib tosylate; Assigned to Arm(s): Sorafenib, Multikinase Inhibitor, Tablet
B: N/A
C: Arm Label: Arm I (radioembolization); Type: EXPERIMENTAL; Interventions: Radiation: yttrium Y 90 glass microspheres | Arm Label: Arm II (transarterial chemoembolization [TACE]); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin | Intervention Type: RADIATION; Name: yttrium Y 90 glass microspheres; Assigned to Arm(s): Arm I (radioembolization) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm II (transarterial chemoembolization [TACE])
D: Arm Label: sorafenib group; Type: ACTIVE_COMPARATOR; Interventions: Drug: sorafenib | Arm Label: radioembolization group; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIR-Sphere | Intervention Type: DRUG; Name: sorafenib; Assigned to Arm(s): sorafenib group | Intervention Type: DRUG; Name: SIR-Sphere; Assigned to Arm(s): radioembolization group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Brief Summary: The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.


Options:
A: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard surgery | Arm Label: Mohs; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mohs micrographic surgery | Intervention Type: PROCEDURE; Name: standard surgery; Assigned to Arm(s): standard surgery | Intervention Type: PROCEDURE; Name: Mohs micrographic surgery; Assigned to Arm(s): Mohs
C: Arm Label: LDE225 200 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Arm Label: LDE225 800 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Intervention Type: DRUG; Name: LDE225; Assigned to Arm(s): LDE225 200 mg, LDE225 800 mg
D: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: GDC-0449 | Arm Label: GDC-0449; Type: EXPERIMENTAL; Interventions: Drug: GDC-0449 | Intervention Type: DRUG; Name: GDC-0449; Assigned to Arm(s): GDC-0449, Sugar pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy
Brief Summary: Randomized, double-blind placebo controlled trial of fish oil to decrease inflammation in pregnancy.


Options:
A: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm
B: Arm Label: Docosahexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): Docosahexaenoic Acid (DHA) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Omega-3 Fish Oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fish Oil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fish Oil; Assigned to Arm(s): Omega-3 Fish Oil, Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA Supplements | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplements; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Supplements; Assigned to Arm(s): 2

Answer: C